DOCSLIB.ORG

US20170368167A9.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE MAIN TEA ETA USAITOA 20170368167A9 MA MA MA MA MA MAITI ( 19 ) United States ( 10 ) Pub . No .: US 2017/ 0368167 A9 ( 12) Patent Application Publication (48 ) Pub . Date : Dec . 28 , 2017 Agadjanyan et al. CORRECTED PUBLICATION ( 54 ) COMPOSITIONS AND METHODS RELATED (60 ) Provisional application No . 61 /691 ,607 , filed on Aug . TO NEUROLOGICAL DISORDERS 21 , 2012 , provisional application No . 61/ 792 , 770 , filed on Mar. 15 , 2013 . @(71 ) Applicants : The Institute for Molecular Medicine , Huntington Beach , CA (US ) ; VAXINE Publication Classification PTY LTD , Adelaide (AU ) (51 ) Int. Cl. A61K 39 /39 ( 2006 .01 ) @( 72 ) Inventors: Michael Agadjanyan , Huntington A61K 39 /00 ( 2006 .01 ) Beach , CA ( US) ; Anahit Ghochikyan , (52 ) U . S . CI. Huntington Beach , CA ( US ) ; Nikolai CPC . .. .. A61K 39 /39 ( 2013 . 01) ; A61K 39 / 0007 Petrovsky , Adelaide ( AU ) ( 2013 . 01 ) ; A61K 2039 / 55583 ( 2013 .01 ) ; A61K 2039/ 55505 (2013 . 01 ) ; A61K 2039/ 575 @(21 ) Appl. No. : 15 / 174 ,709 ( 2013 . 01 ) ; A61K 2039 /55561 ( 2013 .01 ) (57 ) ABSTRACT @(22 ) Filed : Jun . 6 , 2016 The present technology relates to compositions comprising inulin particles for use in the enhancement of immune Prior Publication Data responses to neuronal self -antigens for treating or preventing ( 15) Correction of US 2017 /0239349 A1 Aug. 24 , 2017 neurodegenerative diseases , in a subject . Also provided are See (63 ) and (60 ) Related U . S . Application Data . pharmaceutically acceptable compositions comprising : par ticles of inulin ; a substance comprising one or more patho (65 ) US 2017 /0239349 A1 Aug . 24 , 2017 gen -associated molecular patterns ( PAMPs) ; and a neuronal self - antigen fused to carrier , and methods and uses of the composition for inducing or modulating an immune Related U . S . Application Data response in a subject, such as modulating an immune (63 ) Continuation - in -part of application No . 14 /628 , 023 , response to a neuronal self - antigen as a vaccine . Also filed on Feb . 20 , 2015 , which is a continuation of provided are vaccine compositions comprising inulin par application No. PCT /US2013 /055877 , filed on Aug . ticles , and an antigen - binding carrier material , and methods 20 , 2013 and uses of the vaccine . Patent Application Publication Dec . 28 , 2017 Sheet 1 of 65 US 2017 /0368167 A9 FIG . IA FIG . ID ALIUON00)* wwws :9 1chd * EIN oda 909 99** N1 ML"Giz 009 TIV = 2000Ali COV*9 ( Bi All 9: 0 * * 003 *HP NEL :3 mil312 900 +Nilm ALL#* . M ALAAIL*09 #12 40 od Nupu + 2014All*109 . vrnirnar . juusemuagakQowwwx) Anti-akustizalgGza(00sm) porting my wwwwwwwwww This Per wonnnnnnnnnnnnnn mininnnnnnnnnnn +19 *AL *. 36 Do do 29 o999 :NIP Ald ALE*HOZ Mai Ald 09 045*WIR árlón909 NIP TH4 TIV*T All #odabraz . All 9400900 MIL Oroz Aodo* B2 #p90 * W ALL- ALL +O2 ..Al * * All # FIG . IB FIG . IC Patent Application Publication Dec . 28, 2017 Sheet 2 of 65 US 2017 /0368167 A9 FIG . 2A FIG . 2B ??????????? ? ? * * ! ?? .Fire ??? ??? * ???? ** ? ???:: ?????: FIG , 2G * * ????? ??????? ??? ??: ?? # " [ar ?? illaha #? ????: ?? ???": .iiii ?? ?? ?? # Flu | # | .?? . ? 43 *4334333334335 ? * 3233333% ? 33% * * 33 " " ???? ? ?? F ? ???FIGE FI ??, F Patent Application Publication Dec . 28 , 2017 Sheet 3 of 65 US 2017 /0368167 A9 FIG . 3A FIG . 3B oxuanyar*00)90(COL zururi *00)W 90, All* Od * * All HOTES C odoh Alk# les AllWideAll od ALL# .M Kead000 www *00)1991 UZUN postao)ezo czuanyuru BUENO RE 90 All*filled TIV+CD +020 ALL++ ALL FOG940 TEY+ On FIG . 3C FIG . 3D Patent Application Publication Dec . 28 , 2017 Sheet 4 of 65 US 2017 /0368167 A9 FIG . 4A FIG . 4B 981kotwakwao)( ezumuBUY zuoniuk-muyNo. 500)( DEX+Cp62237 *Cpoza 5 * TIV# PDmik +Op61668 1444 #CG2006 ???????tuzzedot *** ????#0902216 ?? Erza 91#00)* 1954)@o* Emenigusguy Anti- *4922000 *CpG2399 #CpG2000 #Cp02216* + CPGIGGE* TIV+POMIK #C0C2395 *PG2008 #Cp62214 *8991000 * FIG . 40 FIG . 4D Patent Application Publication Dec . 28 , 2017 Sheet 5 of 65 US 2017 /0368167 A9 FIG . SA FIG . SB wwwwwww 08G wwwwwainnainmaalalaban annanna vir *00)910 Swinan wwwwww OMODestan) Anti-katies ???????????????????????????????????????? www wawinan Antimabios mannanna Rodinn Www BIO ouRablo 1001+ SalinaRabius10 Rabia +dIN # *PDI* TOP pusaq # 1011Raba me* 5#Niposaqes line 10x1Raivia +c+IN 1011Rabies +Salitte Toul Kabies #PDM 1061001 Mabies #Saline 1001 Rabies #PDmix : 1Tel win G1(004mm) KotRabias win minnnnnnn www Anti-Rus G2a(00sten gustong A Atttt HowRabies Rabicdin #P Dili 1030Rabies #Pomix ** ToutEtablasttaline 1024Babics =Saline PoulRabies Tol*Saline1021 Rabitudin Rabimnu9Pprin noulRabits #01+Saline3444 Rabimsed 10 ???HowRabiesoforas FIG . SC FIG . 5D 1.2 : : : Patent Application Publication Dec . 28 , 2017 Sheet 6 of 65 US 2017 /0368167 A9 wwwg Total196(OD.sonm) wysoista . LIA. XW0dAL 900x900 Uesowat veUuBuod, Vysowed (w I FIG . 6B6B sx00)Wo1901 wwwwwwwwwwwassenenwaarvan Antinfluenza Saa *LTA XWOd*A 90079d5* vesowkZ WBuuewoon PamCSK4 Patent Application Publication Dec . 28 , 2017 Sheet 7 of 65 US 2017 /0368167 A9 FIG . 6C Jonssoningannaninigasandosimn (uu0$700)190201 ezuantomuy ogamatanoprositoareparing 1 .9002900 wesomez lillVO* FIG . 6D (wuoxo)ezoöleQL Web ZuenguUV V1 XuddAl 900zodo VESOWA veguewody sowest Patent Application Publication Dec . 28 , 2017 Sheet 8 of 65 US 2017 /0368167 A9 FIG . 7A TotalIgG(ODasorm) Anti-influenza *POVE *MPLA) lagellin Prav(U) CSKPok[t : *) MPLA Poly(0) *VALP 00000* FlatéliliaMALP *Home 1961oo)fosy zuenburguy FIG . 7B SOUVE muthaliliilien#MPL Sad* Poly (0 ) PLA ALP Polvuj Plageliin PolveuSOLEREDE hladmin*WALB 9007909 PO zuengumpay IgG2a(ODscann) het nie ????WE )* *#BLA Flagodilo MoltCOGR009)Watcsk w#Polych : )UPLA # Flagaillit MALPA Poly800zodo (U) FIG . 7C romis ) FIG. 70 Patent Application Publication Dec . 28 , 2017 Sheet 9 of 65 US 2017 /0368167 A9 FIG . 8A FIG . 8B *18X(00458) Anti-H6IgG(00450 5POL HSkg g* DIN SH400L + MP *049 HS100ngdi W FIG . 8C FIG . 8D Anti-51961(00480) Antas(gaza0046 !ttt bis30 ilk+CDG 96Bob 8HPgang • din +Co W30100 #foong (OS400) 109400)4295Swauan wwwwwwwwwwminiw ISHOQUE a 1459 d .GoG CASH NIP 10100g #DIN SMBugo WIP 900 15Tag 58licce FIG . SE FIG . 8F Patent Application Publication Dec . 28 , 2017 Sheet 10 of 65 US 2017 /0368167 A9 FIG . 9A horoscoop mit 88 I C00300€ h wanawake * * minimumorigi ironnement orang ** 41*** * * * ** *: 21 B VW ansstorynot variante * woninis wawwwww wwwwwwwwwwwwwwwwww- %Startingbodyweight post-PR8challenge 823 . * * * * * * * * *. .. * * * * * * * * * * * * *** * * * 4444444 writinis pro song version * 0903008 cerimonia Salina 0. ???? ??? ?? ??2 ?? ?? ?? ??? 4? ?? 6 ???? ?? 8 ???? ?? ? ????10 Days after challenge FIG . 9B kurdistangomitopitongA A PR8PR8+ + diNd NCog/ + CPG 11 %StartingBodyweight moting Sains www on PRS * Saline PR8 * CpG 0 2 4 6 8 10 Days post challenge Patent Application Publication Dec . 28 , 2017 Sheet 11 of 65 US 2017 /0368167 A9 Hemagglutination inhibition and neutralizing antibody Uters during vaccination Hemagglutination - nhbition Antibody at booster dose , Day - 21 prior to challenge 512 seis 256susitikimas H H JobVH H 8 Sestdienas H 22.54g+Ad1pm ow+Bis27.50g*Ad1 apy+Bits27.5ug“Ad2 zoX+Bilg'a VaccineNoAd ONO ZpYongzz 225ugAd2Once Group FIG . 10A Patent Application Publication Dec . 28 , 2017 Sheet 12 of 65 US 2017 /0368167 A9 Hemagglutination - Inhbition Anibody on Day 7 prior to challenge E + k 101VH sweet 2 H I HH +A15u822. Onuo 7.519+Ad17Adte*g57. Ad2+54g7.A02549*7. 22.5ug*Adi zou+busz VaccineNoAd 22.500Ad2Once HOND a FIG . 10B Patent Application Publication Dec . 28 , 2017 Sheet 13 of 65 US 2017 /0368167 A9 Microneutralization antibody at booster dose , day 21 prior to challenge 2048 JauuogezjemnalogW 7.6ugAdi 7.5vg+Ad2 22.6ug*Adt 22.54g*Ad2 Vaccine*NoAd Oudoo 22519-A02Once Group FIG . 10C Patent Application Publication Dec . 28 , 2017 Sheet 14 of 65 US 2017 /0368167 A9 Microneutralization antibody at booster dose . day - 21 prior to chalenge H + MicroneutralizationTiter He + * * * oooooooooooooo 750gAd)von Onuo 7.5ugAd2 22.5ug*Adil zov+Bigzz Vaccine*NoAd 22.500 226ug*Ad2Once Group FIG . 10D Patent Application Publication Dec . 28 , 2017 Sheet 15 of 65 US 2017 /0368167 A9 100%:22.5ugInadz(once) OnsZpYuk. 100%.7,5ugnAdi aurpes*oricca:%29 *100%22.5ugnadieienaaris100%22.5ugsnsd2 kinge009. companiesnoiementS22629ONQuest . mesto ELI wwww HOWCACAOC Steinman Dosorown L w 000000 00000 OLL A wwwDay6Saline*InAdi Day5,25:Salinesnad2 inw ogooo000000dinniwwwwwwww 6 incon.Day6SalineSaline n 8 o w wamework 2 StudyDay Kawin i ndooooooooM AMA 000000 ?????????????????????????????????oo?????????????????????????????????????? book wwwwwwwwwww ** * * d seccovering wwwww too Survivalproportions W 9 wwwmero0000000wwwiinanaman € ainimiininanini 7 wamininiai000winning FIG.11 100 onmintainininn i vidio da ????????????????????????????????????????????0 survival Percent Patent Application Publication Dec . 28 , 2017 Sheet 16 of 65 US 2017 /0368167 A9 FIG . 12A 22 . 5 ug + Ad1 * * * * * * * * * * * * * * * * * * Www xvWWW ? ? ? ? ? ? ? ? ? ? percentweightchange Birmingham 11 13 7 . 5 ug + Ad1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? S mimpinning percentweightchange trand 1113 DPI FIG . 12C Patent Application Publication Dec . 28 , 2017 Sheet 17 of 65 US 2017 /0368167 A9 FIG . 12B in 22 .5 ug * Adt percentweightchange . .. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * TTTTT WeightChangeafterchallenge DA 7 . 5 mg * Ad2 YYYYYYYYYYY TITI percentweightchange 77 7 OPI FIG . 12D Patent Application Publication Dec . 28 , 2017 Sheet 18 of 65 US 2017 /0368167 A9 Lord : : : : : : 22. 5 g
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al

    (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al

    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
  • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (Nsaids)

    NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (Nsaids)

    NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) A. Description Interfere with prostaglandin synthesis Alleviate inflammation and subsequent discomfort of rheumatoid conditions (GA) Available in oral and parenteral (IM) preparations CYCLOOXYGENASE INHIBITORS : are preferred because it does not decrease the cytoprotective lining of the stomach. Celebrex (Celecoxib) Vioxx (Rofecoxib)(No longer on market as of September 2004) Bextra (Valdecoxib)(No longer on market as of April 2005) There are also other COX-2 Inhibitors being developed, including: Prexige Lumiracoxib) Arcoxia (Etoricoxib) B. Examples Diclofenac (Voltaren) Etodolac (Lodine) Ibuprofen (Motrin) Naproxen (Naprosyn) Salicylates (ASA) COX-2 SELECTIVE INHIBITORS are the newest of the NSAIDs KETOROLAC is the only NSAID that can be administered by injection (intramuscularly or intravenously) and is indicated for the short-term use of severe to moderate pain. C. Major Side Effects GI irritation (local effect) Skin rash (hypersensitivity) Blood dyscrasias (decreased RBCs, WBCs, platelet synthesis) CNS and GU disturbances D. Nursing Care Administer with meals to reduce GI irritation Monitor blood work Assess vital signs Instruct client to report the occurrence of any side effects to the physician Encourage diet rich in nutrient-dense foods such as fruits, vegetables, whole grains, and legumes to improve and maintain nutritional status and prevent possible drug-induced nutrient deficiencies ANTIGOUT AGENTS (Uricosuric agent) A. Description Act by decreasing uric acid
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • 3258 N:O 1179

    3258 N:O 1179

    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • ¬Chronic Immune-Mediated Inflammatory Diseases And

    ¬Chronic Immune-Mediated Inflammatory Diseases And

    The Association Between Chronic Immune-Mediated Inflammatory Diseases and Cardiovascular Risk Jose Miguel Baena-Díez1,2,3, Maria Garcia-Gil4,5,6, Marc Comas-Cufí4,5, Rafel Ramos4,5,6,7, Daniel Prieto-Alhambra8,9, Betlem Salvador-González1,10, Roberto Elosua1, Irene R. Dégano1, Judith Peñafiel1, Maria Grau1,11* 1REGICOR Study Group - Cardiovascular Epidemiology and Genetics, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain 2La Marina Primary Care Centre and Primary Care Research Institute Jordi Gol, Catalan Institute of Health, Barcelona, Spain 3Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Spain 4Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain 5ISV Research Group, Research Unit in Primary Care, Primary Care Services, Girona, Catalan Institute of Health (ICS), Spain 6TransLab Research Group, Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain 7Biomedical Research Institute, Girona (IdIBGi), ICS, Spain 8Musculoskeletal diseases Research Group (GREMPAL), Primary Care Research Institute Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain 9Musculoskeletal Pharmaco- and Device Epidemiology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom 10Florida Sud Primary Care Centre and Primary Care Research Institute Jordi Gol, Catalan Institute of Health, L’Hospitalet de Llobregat, Spain 11University of Barcelona, Spain *Corresponding
  • Hexachlorophenum Hexaminolaevulinas Hydrochloridum

    Hexachlorophenum Hexaminolaevulinas Hydrochloridum

    29 Hexachlorophenum Heksaklorofeeni Hexaklorofen Hexachlorophene Hexaminolaevulinas Heksaminolevulinaattihyd- Hexaminolevulinathydro- Hexaminolevulinate hyd- hydrochloridum rokloridi klorid rochloride Hexapropymatum Heksapropymaatti Hexapropymat Hexapropymate Hexobarbitalum Heksobarbitaali Hexobarbital Hexobarbital Hexocyclium Heksosyklium Hexocyklium Hexocyclium Hexoprenalinum Heksoprenaliini Hexoprenalin Hexoprenaline Hexylnicotinatum Heksyylinikotinaatti Hexylnikotinat Hexyl nicotinate Hexylresorcinolum Heksyyliresorsinoli Hexyh-esorcinol Hexylresorcinol Hirudinum Hirudiini Hirudin Hirudin Histamini Histamiinidihydrokloridi Histamindihydroklorid Histamine dihydrochloride dihydrochloridum Histaminum Histamiini Histamin Histamine Histapyrrodinum Histapyrrodiini Histapyrrodin Histapyrrodine Hisb-elinum Histreliini Histrelin Histrelin Homatropini Homati'opiinimetyyli- Homatropinmetylbromid Homatropine methylbromidum bromidi methylbromide Homatropinum Homatropiini Homatropin Homatropine Hormonum parathyroidum Paratyroidihormoni Parathormon Parathyroid hormone (rdna) (rdna) Hyaluronidasum Hyaluronidaasi Hyaluronidas Hyaluronidase Hydralazinum Hydralatsiini Hydralazin Hydralazine Hydrochlorothiazidum Hydroklooritiatsidi Hydroklortiazid Hydrochlorothiazide Hydrocodonum Hydrokodoni Hydrokodon Hydrocodone Hydrocortisonum Hydrokortisoni Hydrokortison Hydrocortisone Hydroflumethiazidum Hydroflumetiatsidi Hydroflumetiazid Hydroflumethiazide Hydromorphonum Hydromorfoni Hydromorfon Hydromorphone Hydrotalcitum Hydrotalsiitti Hydrotalcit Hydrotalcite
  • Body Mass Index and Treatment Response to Subcutaneous Abatacept in Patients with Psoriatic Arthritis: a Iain B Mcinnes

    Body Mass Index and Treatment Response to Subcutaneous Abatacept in Patients with Psoriatic Arthritis: a Iain B Mcinnes

    Providence St. Joseph Health Providence St. Joseph Health Digital Commons Articles, Abstracts, and Reports 1-1-2019 Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a Iain B McInnes Gianfranco Ferraccioli Maria-Antonietta D'Agostino Manuela Le Bars Subhashis Banerjee See next page for additional authors Follow this and additional works at: https://digitalcommons.psjhealth.org/publications Part of the Orthopedics Commons, and the Rheumatology Commons Recommended Citation McInnes, Iain B; Ferraccioli, Gianfranco; D'Agostino, Maria-Antonietta; Le Bars, Manuela; Banerjee, Subhashis; Ahmad, Harris A; Elbez, Yedid; and Mease, Philip, "Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a" (2019). Articles, Abstracts, and Reports. 1705. https://digitalcommons.psjhealth.org/publications/1705 This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact [email protected]. Authors Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, and Philip Mease This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/1705 Psoriatic arthritis ORIGINAL ARTICLE Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial Iain B McInnes, 1 Gianfranco Ferraccioli, 2 Maria-Antonietta D'Agostino, 3 Manuela Le Bars,4 Subhashis Banerjee,5 Harris A Ahmad,5 Yedid Elbez,6 Philip J Mease 7 To cite: McInnes IB, ABSTRACT Key messages Ferraccioli G, D'Agostino M-A, Objective This post hoc analysis of the phase III et al.